Phase I trial of ZEN003694 (ZEN-3694) in combination with capecitabine in patients with solid tumors
Contact:
NCT Number:
Protocol:
AAAU8602
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I
The purpose of this study is to test the safety of a drug called ZEN003694 (ZEN-3694), in combination with the usual approach of capecitabine. This study tests different doses of ZEN003694 in combination with capecitabine to see which dose is safer for people. There will be between 21 and 30 people taking part in this study. This drug combination is not approved by the FDA for treatment of the disease being studied.
Are you Eligible? (Inclusion Criteria)
- Are you 18 years of age or older? Have you been diagnosed with metastatic or unresectable cancer, which progressed while you were treated with a regimen including 5-FU or capecitabine? Are you willing to make regularly scheduled visits to the clinic for treatment and evaluation?
Specialty Area(s)
Colon and Rectal Cancer, Liver Cancer, Pancreatic Cancer, Stomach Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
